Drugs for Hemoglobinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 128)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ribavirin |
Approved |
Phase 4 |
|
36791-04-5 |
37542 |
Synonyms:
1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-Î’-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
1-Î’-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
Copegus
Copegus®|RBV|Rebetol®|ribofluranosyl carboxamide|Virazole®
Dermatech brand OF ribavirin
Essex brand OF ribavirin
Grossman brand OF ribavirin
ICN brand OF ribavirin
Merck brand OF ribavirin
NSC-163039
Pfizer brand OF ribavirin
RBV
Rebetol
Rebetron
Rebretron
Ribamide
Ribamidil
Ribamidyl
RIBAPAK
Ribasphere
RIBAV
RIBAVARIN
Ribavirin
|
Ribavirin Capsules
Ribavirin merck brand
Ribavirin Triphosphate
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirin-TP
Ribavirinum
Ribavirinum [INN-Latin]
RIBOFLURANOSYL CARBOXAMIDE
Ribovirin
RTC
RTCA
RTP
SCH 18908
SCH-18908
Three rivers pharmaceuticals brand OF ribavirin
Tribavirin
Varazid
Vilona
VIRAMID
Viramide
VIRAZID
Virazide
Virazole
Virazole 5'-triphosphate
|
|
2 |
|
Peginterferon alfa-2b |
Approved |
Phase 4 |
|
215647-85-1, 99210-65-8 |
|
Synonyms:
Interferon alfa-2b
Intron A
Peginterferon alfa-2b
PEGINTRON
|
PEG-INTRON
PegIntron®|Sylatron®
rIFN-alpha-2b
Unitron PEG
|
|
3 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 4 |
|
198153-51-4 |
|
Synonyms:
PEGASYS
PEG-IFN alfa-2A
PEG-Interferon alfa-2A
PEGINTERFERON ALFA-2A
PEGYLATED IFN-ALPHA-2A
Pegylated Interfeaon alfa-2A
|
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
RO-258310000
ROFERON-A
|
|
4 |
|
Deferasirox |
Approved, Investigational |
Phase 4 |
|
201530-41-8 |
214348 5493381 |
Synonyms:
4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid
DEFERASIROX
Deferasiroxum
Deferasiroxum [inn-latin]
Exjade
ICL 670
ICL 670a
|
ICL670
ICL-670
ICL670a
ICL-670a
Jadenu
JADENU SPRINKLE
|
|
5 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
6 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
7 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
8 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
9 |
|
Interferon alpha-2 |
|
Phase 4 |
|
|
|
10 |
|
interferons |
|
Phase 4 |
|
|
|
11 |
|
Interferon-alpha |
|
Phase 4 |
|
|
|
12 |
|
Interferon-alfa-1b |
|
Phase 4 |
|
|
|
13 |
|
Iron Chelating Agents |
|
Phase 4 |
|
|
|
14 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
15 |
|
Iron |
Approved |
Phase 3 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
16 |
|
Vidarabine |
Approved, Investigational |
Phase 2, Phase 3 |
|
24356-66-9 |
21704 |
Synonyms:
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
9 beta Arabinofuranosyladenine
9 beta D Arabinofuranosyladenine
9-b-D-Arabinofuranosyl-9H-purin-6-amine
9-b-D-Arabinofuranosyladenine
9-beta-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-adenine
9-Î’-D-arabinofuranosyl-9H-purin-6-amine
9-Î’-D-arabinofuranosyladenine
a, alpha-Ara
a, Ara
a, beta-Ara
Adenine arabinoside
alpha Ara a
alpha D Arabinofuranosyladenine
alpha-Ara a
alpha-D-Arabinofuranosyladenine
Ara a
ARA-a
Araadenosine
|
Ara-ATP
Arabinofuranosyladenine
Arabinoside adenine
Arabinoside, adenine
Arabinosyl adenine
Arabinosyladenine
Armes
beta Ara a
beta-Ara a
CI-673
Monarch brand OF vidarabine
NSC-247519
NSC-404241
Parke davis brand OF vidarabine
Spongoadenosine
Vidarabine
Vidarabine anhydrous
VIDARABINE MONOHYDRATE
Vidarabinum
Vira a
Vira-a
ViraA
|
|
17 |
|
Deferiprone |
Approved |
Phase 3 |
|
30652-11-0 |
2972 |
Synonyms:
1,2 Dimethyl 3 hydroxy 4 pyridinone
1,2 Dimethyl 3 hydroxypyrid 4 one
1,2 Dimethyl 3 hydroxypyridin 4 one
1,2-Dimethyl-3-hydroxy-4-pyridinone
1,2-Dimethyl-3-hydroxypyrid-4-one
1,2-Dimethyl-3-hydroxypyridin-4-one
3 Hydroxy 1,2 dimethyl 4 pyridinone
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
3-Hydroxy-1,2-dimethyl-4-pyridinone
APO-066
APO-66
CP20
CP-20
DEFERIPRON
DEFERIPRONA
DEFERIPRONE
DÉFÉRIPRONE
|
DEFERIPRONI
DEFERIPRONUM
DEFERYPRON
DIMETHYLHYDROXYPYRIDONE
DMOHPO
DN-18001AF
DN-180-01-AF
Ferriprox
HDMPP
HDMPP CPD
HDPP
L1
L-1
L1 Oral chelate
PL1
PL-1
|
|
18 |
|
Busulfan |
Approved, Investigational |
Phase 2, Phase 3 |
|
55-98-1 |
2478 |
Synonyms:
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Dimesyloxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulphonoxybutane
Bisulfex
Bisulphex
BUSILVEX
BUSULFAN
Busulfan glaxosmithkline brand
Busulfan orphan brand
Busulfan wellcome
Busulfan wellcome brand
Busulfano
Busulfanum
Busulfex
BUSULFEX IV
Busulphan
Busulphane
Busulphano
Busulphanum
Butanedioldimethanesulfonate
Buzulfan
Citosulfan
Glaxo wellcome brand OF busulfan
GlaxoSmithKline brand OF busulfan
Glyzophrol
Leucosulfan
|
Leucosulphan
Mablin
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
Myeleukon
Myeloleukon
Myelosan
Mylecytan
Myleran
Myléran
Myleran Tablets
N-Butane-1,3-di(methylsulfonate)
NCI-C01592
NSC-750
Orphan brand OF busulfan
Sulfabutin
Sulphabutin
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene dimethane sulfonate
Tetramethylenester kyseliny methansulfonove
Wellcome brand OF busulfan
Wellcome, busulfan
|
|
19 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
20 |
|
Penicillins |
|
Phase 3 |
|
|
|
21 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
22 |
|
Deferoxamine |
Approved, Investigational |
Phase 2 |
|
70-51-9 |
2973 |
Synonyms:
b, Deferoxamine
b, Desferrioxamine
Deferoxamide b
Deferoxamin
Deferoxamina
Deferoxamine
Déferoxamine
Deferoxamine b
Deferoxamine mesilate
Deferoxamine mesylate
Deferoxamine methanesulfonate
Deferoxaminum
Deferoximine
Deferrioxamine
Deferrioxamine b
Desferal
|
Desferioximine
Desferrioxamine
Desferrioxamine b
Desferrioxamine b mesylate
Desferroxamine
DF b
DFO
DFOA
DFOM
Mesilate, deferoxamine
Mesylate, deferoxamine
Mesylate, desferrioxamine b
Methanesulfonate, deferoxamine
N-Benzoylferrioxamine b
NSC-527604
|
|
23 |
|
Hydroxyurea |
Approved |
Phase 1, Phase 2 |
|
127-07-1 |
3657 |
Synonyms:
Biosupressin
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroxyamic acid
Carbamoyl oxime
Carbamyl hydroxamate
Carbamyl hydroxamic acid
Droxia
Droxia®|Hydrea®|hydroxycarbamide|Siklos®|SQ-1089|Xromi®
Hidrix
Hidroxicarbamida
HU
Hydrea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamidum
|
Hydroxycarbamine
Hydroxyharnstoff
Hydroxylurea
HYDROXYUREA
Hydura
Hydurea
Idrossicarbamide
Idrossicarbamide [Dcit]
Litaler
Litalir
N-Carbamoylhydroxylamine
N-HYDROXYUREA
NSC-32065
Oncocarbide
Onco-Carbide
Oxyurea
SIKLOS
SQ-1089
Sterile Urea
Ureaphil
|
|
24 |
|
Clofarabine |
Approved, Investigational |
Phase 2 |
|
123318-82-1 |
119182 |
Synonyms:
(2R,3R,4S,5R)-5-(6-Amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
2 Chloro 2' arabino fluoro 2' deoxyadenosine
2 Chloro 2' fluoroarabino 2' deoxyadenosine
2-Chloro-2'-arabino-fluoro-2'-deoxyadenosine
2-Chloro-2'-fluoroarabino-2'-deoxyadenosine
2-Chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine
2-Chloro-9-(2'-deoxy-2'-fluoro-b-D-arabinofuranosyl)adenine
2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine
2-Chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine
2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine
2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arbinofuranosyl)adenine
2-Chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine
|
2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
CAFdA
CAFdA|Cl-F-araA|Clolar®|Evoltra®
CL-F-Ara-a
CL-F-ARAA
CLOFARABIN
Clofarabina
CLOFARABINE
Clofarabinum
Clofarex
Clolar
Evoltra
|
|
25 |
|
Thiotepa |
Approved, Investigational |
Phase 1, Phase 2 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
NSC-6396
Rethio
Tepadina
Tepadina®|Thioplex®
Tespa
Tespamin
Thio tepa
|
Thiophosphamide
Thioplex
Thio-tepa
THIOTEPA
THIOTEPA 或 THIOTEPA
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
26 |
|
Abatacept |
Approved |
Phase 1, Phase 2 |
|
332348-12-6 |
|
Synonyms:
ABATACEPT
ABATACEPT (GENETICAL RECOMBINATION)
Abatacept recombinant
BMS-188667
BMS-188667|CTLA4-IgG4m|Orencia®|RG-1046|RG-2077
CTLA4IG
CTLA4-IG
|
CTLA4IGG4M
CTLA4-IGG4M
ORENCIA
ORENCIA CLICKJECT
RG-1046
RG-2077
|
|
27 |
|
Methotrexate |
Approved |
Phase 1, Phase 2 |
|
1959-05-2, 59-05-2 |
4112 126941 |
Synonyms:
[<sup>3</sup>H]-methotrexate
2-[(4-{[(4-amino-2-imino-2,3-dihydropteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioate
4-Amino-10-methylfolate
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-Amino-N(10)-methylpteroylglutamic acid
ABITREXATE
Abitrexate®|amethopterin|Nordimet®|Rasuvo®
Amethopterin
Amethopterine
Antifolan
Arbitrexate
CL-14377
Dicesium salt methotrexate
EBETREX
EMT-25299
Emtexate
EMTEXATE HIGH-POT
EMTEXATE PF
Emtexic acid
FOLEX
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
MAXTREX
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
Méthotrexate
Methotrexate hydrate
|
Methotrexate sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
METOJECT
Metotrexato
Mexate
MEXATE-AQ
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
NSC-740
Otrexup
OTREXUP PFS
R-9985
RASUVO
Rheumatrex
R-METHOTREXATE
Sodium, methotrexate
TCMDC-123832
TCMDC-125488
TCMDC-125858
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexate
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexic acid
Trexall
Xatmep
ZLATAL
|
|
28 |
|
Melphalan |
Approved |
Phase 1, Phase 2 |
|
148-82-3 |
4053 460612 |
Synonyms:
2-Amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate
2-Amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoate
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
AIKERAN
ALANINE NITROGEN MUSTARD
Alkeran
CB-3025
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
L-PAM
L-Phenylalanine mustard
L-PHENYLALANINE MUSTARD (L-PAM)
L-SARCOLYSIN
L-Sarcolysine
L-Sarkolysin
Medphalan
MELFALAN
Melfalano
Melphalan
|
Melphalanum
Mephalan
Merphalan
MLP673
Mustard, phenylalanine
NCI-C04853
NSC-241286
NSC-8806
p-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
p-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
Sarcolysin
Sarcolysine
Sarkolysin
SK 15673
SK-15673
|
|
29 |
|
Treosulfan |
Approved, Investigational |
Phase 2 |
|
299-75-2 |
9296 |
Synonyms:
(2S,3S)-Threitol 1,4-bismethanesulfonate
1,4-Dimethanesulfonate(2S,3S)-threitol
1,4-Dimethanesulfonatel-(+ )-threitol
1,4-Dimethanesulfonatel-threitol
2,3-Dihydroxy-4-(methanesulfonyloxy)butyl methanesulfonic acid
2,3-Dihydroxy-4-(methanesulphonyloxy)butyl methanesulphonate
2,3-Dihydroxy-4-(methanesulphonyloxy)butyl methanesulphonic acid
DHB
Dihydroxybusulfan
Dihydroxymyleran
L-Dihydroxybusulfan
L-Threitol 1,4-dimethanesulfonate
L-Threitol, 1, 4-bis(methanesulfonate)
|
L-Threitol-1, 4-bis(methanesulfonate)
L-Threitol-1,4-bis(methanesulfonate)
L-Threitol-1,4-bismethanesulfonate
L-Threityl dimesylate
OVASTAT
Treosulfan
Treosulfan, ((r*,r*)-(+-))-isomer
Treosulfan, (R-(r*,r*))-isomer
Treosulfan, (r*,r*)-isomer
Treosulfan, (r*,s*)-isomer
Treosulphan
Tresulfan
|
|
30 |
|
Fludarabine |
Approved |
Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
31 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 2 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
32 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
33 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
34 |
|
Alemtuzumab |
Approved, Investigational |
Phase 2 |
|
216503-57-0 |
|
Synonyms:
ALEMTUZUMAB
ALEMTUZUMAB (GENETICAL RECOMBINATION)
CAMPATH
campath 1H|Campath®|campath-1H|Lemtrada®
CAMPATH MABCAMPATH
CAMPATH MABCAMPATH, LEMTRADA
|
CAMPATH-1H
GZ402673
GZ-402673
LDP-03
LEMTRADA
MABCAMPATH
|
|
35 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
36 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
37 |
|
Phenytoin |
Approved, Vet_approved |
Phase 2 |
|
57-41-0 |
1775 |
Synonyms:
5,5-Diphenylhydantoin
5,5-Diphenylimidazolidine-2,4-dione
5,5-Diphenyl-imidazolidine-2,4-dione
5,5-Diphenyltetrahydro-1H-2,4-imidazoledione
5,5-Dwufenylohydantoina
Aleviatin
Antisacer
Auranile
Causoin
Citrullamon
Citrulliamon
Comital
Comitoina
Convul
Danten
Dantinal
Dantoinal
Dantoinal klinos
Dantoine
Denyl
Didan TDC 250
Difenilhidantoina
Difenilhidantoina [Spanish]
Difenin
Difetoin
Difhydan
Dihycon
Dihydan
Di-Hydan
Dihydantoin
DILABID
Di-Lan
DILANTIN
Dilantin acid
Dilantin®|Epanutin®|Phenytex®|phenytoin sodium
DILANTIN-125
DILANTIN-30
Dilantine
Dillantin
Dintoin
Dintoina
Diphantoin
Diphedal
Diphedan
Diphenat
Diphenin
Diphenine
Diphentoin
Diphentyn
Diphenylan
Diphenylan sodium
Diphenylhydantoin
Diphenylhydantoinate, sodium
Diphenylhydantoine [French]
Diphenylhydatanoin
Di-Phetine
Ditoinate
DPH
Ekko
Elepsindon
Enkelfel
Epamin
Epanutin
Epasmir 5
Epdantoin Simple
Epdantoine simple
Epelin
Epifenyl
Epihydan
Epilan
Epilan D
Epilan-D
Epilantin
Epinat
Epised
Eptal
Eptoin
Fenantoin
Fenidantoin s
Fenitoin
Fenitoina
Fenitoina [INN-Spanish]
|
Fentoin
Fenylepsin
Fenytoin Dak
Fenytoine
Gerot-epilan-D
Hidan
Hidantal
Hidantilo
Hidantina
Hidantina senosian
Hidantina vitoria
Hidantomin
Hindatal
Hydantal
Hydantin
Hydantoin
Hydantoinal
Hydantol
Ictalis simple
Idantoil
Idantoin
Iphenylhydantoin
Kessodanten
Labopal
Lehydan
Lepitoin
Lepsin
Mesantoin
Minetoin
Neos-Hidantoina
Neosidantoina
Novantoina
Novophenytoin
NSC-8722
Om hidantoina simple
Om-Hydantoine
Oxylan
Park davis brand OF phenytoin
Pfizer brand OF phenytoin
Phanantin
Phanatine
Phenatine
Phenatoine
Phenhydan
Phenhydanin
Phenitoin
Phentoin
PHENTYTOIN
PHENYTEK
PHENYTEX
Phenytoin
Phenytoin AWD
Phenytoin pfizer brand
Phenytoin phizer brand
Phenytoin sodium
Phenytoine
Phenytoine [INN-French]
Phenytoin-Gerot
Phenytoinum
Phenytoinum [INN-Latin]
Phizer brand OF phenytoin
Prompt Phenytoin Sodium
Ritmenal
Saceril
Sanepil
Silantin
Sinergina
SM-88 COMPONENT PHENYTOIN
Sodanthon
Sodantoin
Sodanton
Sodium diphenylhydantoinate
Solantin
Solantoin
Solantyl
Sylantoic
Tacosal
Thilophenyl
TOIN
Toin unicelles
Zentronal
Zentropil
|
|
38 |
|
Tacrolimus |
Approved, Investigational |
Phase 2 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
39 |
|
Levetiracetam |
Approved |
Phase 2 |
|
102767-28-2 |
441341 5284583 |
Synonyms:
AGB-101
alpha Ethyl 2 oxo 1 pyrrolidineacetamide
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
DESITREND
e Keppra
ELEPSIA XR
Etiracetam
Etiracetam, R isomer
Etiracetam, R-isomer
Etiracetam, S isomer
Etiracetam, S-isomer
Keppra
KEPPRA XR
Keppra®|Spritam®|UCB L059|UCB-L 059
LEVETIRACETAM
Levetiracetam [INN]
LEVETIRACETAM IN SODIUM CHLORIDE
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levitiracetam
MATEVER
N03AX14
R-Isomer etiracetam
S-Isomer etiracetam
SPRITAM
UCB brand OF levetiracetam
Ucb L059
Ucb L060
UCB-22059
Ucb-L059
UcbL060
Ucb-L060
|
|
40 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
41 |
|
Prednisone |
Approved, Vet_approved |
Phase 2 |
|
53-03-2 |
5865 |
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
42 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
43 |
|
Pyridoxine |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 2 |
|
65-23-6 |
1054 |
Synonyms:
2-METHYL-3-HYDROXY-4,5-BIS(HYDROXYMETHYL)PYRIDINE
2-METHYL-3-HYDROXY-4,5-DI(HYDROXYMETHYL)PYRIDINE
2-METHYL-3-HYDROXY-4,5-DIHYDROXYMETHYLPYRIDINE
2-METHYL-4,5-BIS(HYDROXYMETHYL)-3-HYDROXYPYRIDINE
2-METHYL-4,5-DIMETHYLOL-PYRIDIN-3-OL
3-HYDROXY-2-PICOLINE-4,5-DIMETHANOL
3-HYDROXY-4,5-BIS(HYDROXYMETHYL)-2-METHYLPYRIDINE
3-HYDROXY-4,5-DIMETHYLOL-ALPHA-PICOLINE
3-Hydroxy-4,5-dimethylol-a-picoline
3-Hydroxy-4,5-dimethylol-α-picoline
4,5-BIS(HYDROXYMETHYL)-2-METHYL-PYRIDIN-3-OL
5-HYDROXY-6-METHYL-3,4-PYRIDINEDIMETHANOL
ADERMINE
GRAVIDOX
HEXA-BETALIN
|
HYDOXIN
M.V.I.-12
PIRIDOSSINA
PIRIDOXINA
PYRIDOXIN
PYRIDOXINE
PYRIDOXINE (VIT B6)
Pyridoxine hydrochloride
PYRIDOXINUM
PYRIDOXOL
Pyridoxol hydrochloride
PYRIDOXOLUM
Rodex
VITAMIN B6
|
|
44 |
|
Vitamins |
|
Phase 2 |
|
|
|
45 |
|
Folate |
|
Phase 2 |
|
|
|
46 |
|
Vitamin B9 |
|
Phase 2 |
|
|
|
47 |
|
Vitamin B6 |
|
Phase 2 |
|
|
|
48 |
|
Trace Elements |
|
Phase 2 |
|
|
|
49 |
|
Pyridoxal isonicotinoyl hydrazone |
|
Phase 2 |
|
|
|
50 |
|
Vitamin B Complex |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 86)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C |
Unknown status |
NCT00887081 |
Phase 4 |
PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin |
2 |
A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study) |
Completed |
NCT00673608 |
Phase 4 |
deferasirox |
3 |
Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism |
Completed |
NCT00176852 |
Phase 2, Phase 3 |
Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide |
4 |
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) |
Completed |
NCT00000586 |
Phase 3 |
hydroxyurea |
5 |
Penicillin Prophylaxis in Sickle Cell Disease (PROPS) |
Completed |
NCT00000585 |
Phase 3 |
penicillin |
6 |
Stroke Prevention in Sickle Cell Anemia (STOP 1) |
Completed |
NCT00000592 |
Phase 3 |
|
7 |
Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies |
Completed |
NCT01825512 |
Phase 3 |
Deferiprone;Deferasirox |
8 |
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease |
Recruiting |
NCT05329649 |
Phase 3 |
|
9 |
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia |
Recruiting |
NCT05356195 |
Phase 3 |
|
10 |
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease |
Recruiting |
NCT05477563 |
Phase 3 |
|
11 |
A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease |
Active, not recruiting |
NCT03745287 |
Phase 2, Phase 3 |
|
12 |
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia |
Active, not recruiting |
NCT03655678 |
Phase 2, Phase 3 |
|
13 |
Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia |
Completed |
NCT00001958 |
Phase 2 |
Hydroxyurea |
14 |
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies |
Completed |
NCT00777231 |
Phase 1, Phase 2 |
|
15 |
Multi-Center Study Using Allogeneic Stem Cell Transplantation Following Reduced Intensity Chemotherapy in Patients With Hemoglobinopathies |
Completed |
NCT00153985 |
Phase 2 |
Busulfex;Fludarabine;Alemtuzumab |
16 |
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies |
Completed |
NCT01590628 |
Phase 1, Phase 2 |
NiCord |
17 |
Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes |
Completed |
NCT00004143 |
Phase 2 |
Campath, Chemo and/or TBI Allo SCT |
18 |
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN |
Completed |
NCT02435901 |
Phase 1, Phase 2 |
alemtuzumab (Campath IH);Fludarabine;Melphalan;Cyclosporine;Mycophenolate mofetil;Tacrolimus |
19 |
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral β-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product) |
Completed |
NCT02151526 |
Phase 1, Phase 2 |
LentiGlobin BB305 Drug Product |
20 |
Chelation Therapy of Iron Overload With Oral Pyridoxal Isonicotinoyl Hydrazone |
Completed |
NCT00000588 |
Phase 2 |
Chelation therapy |
21 |
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis |
Completed |
NCT00000595 |
Phase 2 |
deferoxamine |
22 |
Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG) |
Completed |
NCT00000602 |
Phase 2 |
hydroxyurea |
23 |
Multi-centre, Oral Single Dose Experimental and Modelling Study to Evaluate the Pharmacokinetics of Deferiprone in Patients Aged From 1 Month to Less Than 6 Years of Age Affected by Transfusion-dependent Haemoglobinopathies. |
Completed |
NCT01740713 |
Phase 2 |
Deferiprone, dose level 1;Deferiprone, dose level 2;Deferiprone, dose level 3 |
24 |
Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Non-Malignant Hematological Disorders in Children |
Recruiting |
NCT04356469 |
Phase 2 |
|
25 |
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders |
Recruiting |
NCT04644016 |
Phase 2 |
Clofarabine;Fludarabine;Busulfan;Cyclosporine-A;Mycophenolate Mofetil |
26 |
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease |
Recruiting |
NCT04853576 |
Phase 1, Phase 2 |
|
27 |
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders |
Recruiting |
NCT03128996 |
Phase 1, Phase 2 |
RIC regimen;GVHD prophylaxis regimen |
28 |
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders |
Recruiting |
NCT01050855 |
Phase 2 |
RIC: Distal Campath;RIC:Intermediate Campath;RIC: Mini Busulfan |
29 |
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime |
Recruiting |
NCT00920972 |
Phase 1, Phase 2 |
Treatment Plan 1: Stratum 1;Treatment Plan 2: Strata 2, 3, or 4;GVHD Regimen A: UCB Recipients;GVHD Regimen B: BM Recipients |
30 |
A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT) |
Recruiting |
NCT05444894 |
Phase 1, Phase 2 |
|
31 |
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders |
Active, not recruiting |
NCT03301168 |
Phase 1, Phase 2 |
Rimiducid |
32 |
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders |
Active, not recruiting |
NCT03733249 |
Phase 1, Phase 2 |
Rimiducid |
33 |
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease |
Active, not recruiting |
NCT01966367 |
Phase 1, Phase 2 |
|
34 |
Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders |
Active, not recruiting |
NCT02065869 |
Phase 2 |
rimiducid |
35 |
Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases |
Active, not recruiting |
NCT02349906 |
Phase 2 |
Treosulfan;Busilvex |
36 |
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies |
Suspended |
NCT01419704 |
Phase 1, Phase 2 |
|
37 |
A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients |
Terminated |
NCT00968864 |
Phase 2 |
|
38 |
Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia |
Terminated |
NCT00040469 |
Phase 2 |
Campath -1H;Dilantin;Busulfan;Cyclophosphamide |
39 |
Allo SCT From HLA Haploidentical Related Donors Using Sub-Myeloablative Conditioning For Patients With High Risk Hemoglobinopathies: Hemo SS, Hemo SC, Hemo SB0/+ Thalassemia, Homozygous B0/+ Thalassemia or Severe B0/+ Thalassemia Variants |
Terminated |
NCT00040417 |
Phase 2 |
FLUDARABINE;CAMPATH-IH;FK506;G-SCF (Granulocyte-colony stimulating factor) |
40 |
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies |
Terminated |
NCT00489281 |
Phase 2 |
Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Sirolimus;Levetiracetam |
41 |
Allogeneic Stem Cell Transplantation Following Nonmyeloablative Chemotherapy in Patients With Hemoglobinopathies |
Terminated |
NCT00034528 |
Phase 2 |
Busulfan;Fludarabine;FK506;Prednisone |
42 |
Allogeneic Stem Cell Transplantation of CordInâ„¢, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies |
Terminated |
NCT02504619 |
Phase 1, Phase 2 |
|
43 |
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation |
Completed |
NCT00744692 |
Phase 1 |
Reduced Intensity Conditioning |
44 |
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant |
Recruiting |
NCT03249831 |
Phase 1 |
Cyclophosphamide;Pentostatin;Rabbit anti-thymocyte globulin;Tacrolimus;Mycophenolate mofetil |
45 |
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases |
Active, not recruiting |
NCT02231710 |
Phase 1 |
|
46 |
A Single-Center, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Alpha Thalassemia Major |
Enrolling by invitation |
NCT02986698 |
Phase 1 |
|
47 |
Utility of Transient Elastography (Fibroscan) in Estimating Hepatic Iron Concentration in Comparison to MRI in Patients With Transfusion Dependent Hemoglobinopathies |
Unknown status |
NCT02067130 |
|
|
48 |
Retrospective and Prospective Database of COVID-19 Prevalence and Clinical Course in Pediatric and Young Adult Hematology/ Oncology/Stem Cell Therapy Patients in the New York Tri-State Area. |
Unknown status |
NCT04445402 |
|
|
49 |
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism |
Completed |
NCT00427661 |
|
|
50 |
Bone Marrow for Hemoglobinopathy Research |
Completed |
NCT00669305 |
|
|
|